Cullgen
Founded 2018 · 25 employees on LinkedIn · 1 known investors
Cullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach. The company focuses on oncology and immune-related diseases and operates R&D and offices in both China and the United States.
Founders & leadership
Cullgen was founded in 2018 by Ying Luo.
YL
Ying LuoCEO
Investors · 1
Frequently asked questions
- What does Cullgen do?
- Cullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach. The company focuses on oncology and immune-related diseases and operates R&D and offices in both China and the United States.
- Who founded Cullgen?
- Cullgen was founded by Ying Luo in 2018.
- Who are Cullgen's investors?
- Cullgen's investors include 3E Bioventures Capital.